Targeting FSCN1 with an oral small-molecule inhibitor for treating ocular neovascularization

BACKGROUND: Ocular neovascularization is a leading cause of blindness and visual impairment. While intravitreal anti-VEGF agents can be effective, they do have several drawbacks, such as endophthalmitis and drug resistance. Additional studies are necessary to explore alternative therapeutic targets....

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Wen, Ren, Jun-Song, Xia, Min, Zhao, Ya, Ding, Jing-Juan, Chen, Xi, Jiang, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436462/
https://www.ncbi.nlm.nih.gov/pubmed/37596693
http://dx.doi.org/10.1186/s12967-023-04225-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436462/
https://www.ncbi.nlm.nih.gov/pubmed/37596693
http://dx.doi.org/10.1186/s12967-023-04225-0

Ejemplares similares